Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“CAR NK Cells: The Future of Cancer and Autoimmune Therapy?
Chimeric antigen receptor (CAR) NK cell therapy is emerging as a safer, more versatile alternative to CAR T cell therapy, showing promising efficacy in hematologic cancers while reducing severe side effects like CRS, ICANS, and GvHD.
Key Insights from 120 Clinical Trials:
- Strong response rates in B cell malignancies, comparable to CAR T therapy
- Lower toxicity and improved safety profile
- Challenges in solid tumors, with modest efficacy so far
- Expanding applications into autoimmune disorders
Ongoing research aims to enhance CAR NK cell persistence, broaden targets, and refine manufacturing—bringing us closer to next-generation immunotherapies.”
“The clinical landscape of CAR NK cells”
Authors: Lasse Vedel Jørgensen, Emil Birch Christensen, Mike Bogetofte Barnkob, Torben Barington
